CRLCharles River Laboratories
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +44% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A token position, settled Sep 15, 2026, a few days of normal trading to cover. Down 12% since the previous count, unchanged over three months.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CRL is trading
Charles River Laboratories is +92% over the past year while the S&P 500 is +18%: 74 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +44%
vs 200-day average · a clear uptrend
- RSI (14)
- 63
RSI (14) · neutral
- Below its 52-week high
- 2.9%
Below its 52-week high
Details›
- Last close2026-10-09
- $301.83
- 1 monthS&P 500 +2.7%
- +11%
- 1 yearS&P 500 +18%
- +92%
- 5 yearsS&P 500 +88%
- −30%
- vs 50-day average$281.90
- +7.1%
- 52-week high
- $310.95
- 52-week low
- $145.57
- Annualised volatility
- 51%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$3.0M
| Year | Return |
|---|---|
| 2026 (year to date) | +51% |
| 2025 | +8.1% |
| 2024 | −22% |
| 2023 | +8.5% |
| 2022 | −42% |
| 2021 | +51% |
| 2020 | +64% |
| 2019 | +35% |
| 2018 | +3.4% |
| 2017 | +44% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 6 of 10 | +0.15% |
| Feb | 10 | 7 of 10 | +1.6% |
| Mar | 10 | 5 of 10 | −2.8% |
| Apr | 10 | 2 of 10 | −3.7% |
| May | 10 | 7 of 10 | +3.3% |
| Jun | 10 | 7 of 10 | +5.7% |
| Jul | 11 | 8 of 11 | +9.0% |
| Aug | 11 | 4 of 11 | −0.07% |
| Sep | 11 | 5 of 11 | −0.54% |
| Oct | 11 | 6 of 11 | −0.14% |
| Nov | 10 | 6 of 10 | +2.5% |
| Dec | 10 | 7 of 10 | +3.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Diagnostics & Research
The closest names by size in the same industry